Replies to post #94324 on Biotech Values

[DewDiligence]

I don’t think the new Tarceva approval will have a material effect on the price OSIP shareholders get in an eventual buyout. From a commercial standpoint, the NSCLC maintenance indication is marginal in the US and probably non-existent in the EU.